PURPOSE: We qualitatively assessed attitudes regarding use of hypertonic saline nasal irrigation (HSNI) for frequent rhinosinusitis and chronic sinonasal symptoms in a 3-part, multimethod study. METHODS: We conducted semistructured, in-depth interviews with 28 participants who recently used nasal irrigation in studies assessing HSNI. RESULTS: Four themes emerged: (1) HSNI improved self-management of sinus symptoms, creating a sense of empowerment; (2) HSNI produced rapid and long-term improvement in quality of life; (3) participants identified discomfort, time, and mild side effects as barriers to HSNI use; and (4) participants identified aspects of training and at-home use that overcame these barriers. CONCLUSION: HSNI is a safe, well-tolerated, inexpensive, effective, long-term therapy that patients with chronic sinonasal symptoms can and will use at home with minimal training and follow-up. Success with HSNI will likely be improved by patient education.
PURPOSE: We qualitatively assessed attitudes regarding use of hypertonic saline nasal irrigation (HSNI) for frequent rhinosinusitis and chronic sinonasal symptoms in a 3-part, multimethod study. METHODS: We conducted semistructured, in-depth interviews with 28 participants who recently used nasal irrigation in studies assessing HSNI. RESULTS: Four themes emerged: (1) HSNI improved self-management of sinus symptoms, creating a sense of empowerment; (2) HSNI produced rapid and long-term improvement in quality of life; (3) participants identified discomfort, time, and mild side effects as barriers to HSNI use; and (4) participants identified aspects of training and at-home use that overcame these barriers. CONCLUSION: HSNI is a safe, well-tolerated, inexpensive, effective, long-term therapy that patients with chronic sinonasal symptoms can and will use at home with minimal training and follow-up. Success with HSNI will likely be improved by patient education.
Authors: Bruce Barrett; Lucille Marchand; Jo Scheder; Mary Beth Plane; Rob Maberry; Diane Appelbaum; David Rakel; David Rabago Journal: J Altern Complement Med Date: 2003-12 Impact factor: 2.579
Authors: David Rabago; Aleksandra Zgierska; Marlon Mundt; Bruce Barrett; James Bobula; Rob Maberry Journal: J Fam Pract Date: 2002-12 Impact factor: 0.493
Authors: Jens U Ponikau; David A Sherris; Gail M Kephart; Eugene B Kern; David J Congdon; Cheryl R Adolphson; Margaret J Springett; Gerald J Gleich; Hirohito Kita Journal: J Allergy Clin Immunol Date: 2005-08 Impact factor: 10.793
Authors: Kristin A Seiberling; Richard K McHugh; Wilson Aruni; Christopher A Church Journal: Int Forum Allergy Rhinol Date: 2011-06-14 Impact factor: 3.858
Authors: Supriya D Hayer; David P Rabago; Iliya P Amaza; Tony Kille; Christopher L Coe; Aleksandra Zgierska; Larissa Zakletskaia; Marlon P Mundt; Dean Krahn; Chidi N Obasi; Rachel C Molander Journal: Contemp Clin Trials Date: 2015-01-24 Impact factor: 2.226